Bile acid-GCPII inhibitor conjugates to treat inflammatory diseases, including inflammatory bowel disease (IBD)
GCPII inhibitors comprising 2-(phosphonomethyl) pentanedioic acid (2-PMPA) conjugated to a bile acid and their use for treating a disease or condition associated with elevated levels of GCPII, including inflammatory bowel disease.
1 . A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
2 . A method for treating a disease or condition associated with an elevated GCPII activity in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof wherein the disease or condition associated with an elevated GCPII activity is an inflammatory bowel disease.
3 . The method of claim 2 , wherein the inflammatory bowel disease is selected from the group consisting of Crohn's disease (CD) and ulcerative colitis (UC).
4 . The method of claim 2 , wherein the method for treating a disease or condition associated with an elevated GCPII activity inhibits GCPII activity in the subject.
5 . A pharmaceutical composition, comprising at least one compound of claim 1 , in admixture with a pharmaceutically acceptable excipient.
6 . The pharmaceutical composition of claim 5 , further comprising one or more additional therapeutic agents.